[A23-84] Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31
Last updated 05.10.2023
Project no.:
A23-84
Commission:
Commission awarded on 09.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with metastatic non-small cell lung cancer with no sensitizing EGFR mutations or ALK-positive mutations; first-line treatment
Result of dossier assessment:
Unchanged after addendum:
- PD-L1 expression ≥ 50%: added benefit not proven
- PD-L1 expression < 50%: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-29 | Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-31 | Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G23-20 | Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31 | Commission completed |
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision